Your browser is no longer supported. Please, upgrade your browser.
NK NantKwest, Inc. weekly Stock Chart
NantKwest, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own0.70% Shs Outstand101.97M Perf Week-17.68%
Market Cap498.63M Forward P/E- EPS next Y-0.34 Insider Trans-8.23% Shs Float27.73M Perf Month-25.11%
Income-67.50M PEG- EPS next Q-0.20 Inst Own6.10% Short Float13.53% Perf Quarter314.41%
Sales0.04M P/S12161.79 EPS this Y-119.10% Inst Trans6.22% Short Ratio1.68 Perf Half Y285.04%
Book/sh1.38 P/B3.54 EPS next Y54.10% ROA-37.20% Target Price4.00 Perf Year314.41%
Cash/sh0.65 P/C7.54 EPS next 5Y-1.70% ROE-44.90% 52W Range0.95 - 9.90 Perf YTD29.02%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.35% Beta2.68
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin- 52W Low417.37% ATR0.81
Employees147 Current Ratio5.70 Sales Q/Q-61.30% Oper. Margin- RSI (14)38.71 Volatility10.05% 10.27%
OptionableYes Debt/Eq0.01 EPS Q/Q46.90% Profit Margin- Rel Volume0.33 Prev Close4.89
ShortableYes LT Debt/Eq0.00 EarningsMar 03 Payout- Avg Volume2.24M Price4.91
Recom3.00 SMA20-21.69% SMA50-5.84% SMA200122.36% Volume677,801 Change0.51%
May-31-19Downgrade Citigroup Neutral → Sell
Nov-30-18Upgrade Citigroup Sell → Neutral
Oct-17-18Downgrade Citigroup Neutral → Sell
Aug-09-18Upgrade Citigroup Sell → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Mar-17-17Reiterated FBR & Co. Outperform $22 → $9
Jan-24-17Downgrade Jefferies Buy → Hold
Jun-02-16Initiated Raymond James Mkt Perform
Apr-04-16Reiterated Canaccord Genuity Buy $20 → $18
Mar-31-16Reiterated FBR Capital Outperform $30 → $29
Dec-22-15Initiated Canaccord Genuity Buy $20
Oct-28-15Initiated FBR Capital Outperform $30
Aug-24-15Initiated Piper Jaffray Overweight $38
Aug-24-15Initiated MLV & Co Buy $35
Aug-24-15Initiated Jefferies Buy $33
Aug-24-15Initiated Citigroup Buy $45
Jan-17-20 08:42AM  Options Traders Expect Huge Moves in NantKwest (NK) Stock Zacks
Jan-16-20 08:00AM  Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference Business Wire +39.25%
Jan-14-20 08:00AM  NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein Business Wire -27.94%
Jan-13-20 05:22PM  NantKwest Gains 91% After CEO Shares Promising Cancer Result Bloomberg +91.01%
Jan-06-20 11:50AM  Investors Who Bought NantKwest (NASDAQ:NK) Shares A Year Ago Are Now Up 199% Simply Wall St. -5.69%
Dec-20-19 02:55PM  Here is What Hedge Funds Think About Nantkwest Inc (NK) Insider Monkey -6.00%
Dec-16-19 07:00AM  NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS Business Wire +10.76%
Dec-03-19 07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga -6.62%
Dec-02-19 04:05PM  NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers Business Wire -12.21%
Nov-27-19 08:00AM  NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors TEST Business Wire Releases +12.50%
Nov-07-19 04:15PM  NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019 Business Wire
01:14PM  What Kind Of Shareholder Owns Most NantKwest, Inc. (NASDAQ:NK) Stock? Simply Wall St.
Oct-02-19 10:40AM  Does NantKwest, Inc.'s (NASDAQ:NK) CEO Pay Reflect Performance? Simply Wall St.
Aug-27-19 10:21AM  Who Has Been Selling NantKwest, Inc. (NASDAQ:NK) Shares? Simply Wall St.
Jul-11-19 06:58AM  Did Changing Sentiment Drive NantKwest's (NASDAQ:NK) Share Price Down A Painful 82%? Simply Wall St.
Jun-24-19 08:00AM  NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors Business Wire
Jun-06-19 04:10PM  Cheryl Cohen Appointed to NantKwests Board of Directors Business Wire
Jun-04-19 08:00AM  NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients Business Wire -17.83%
07:45AM  NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics Business Wire
Jun-03-19 02:50PM  NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients Business Wire +25.24%
08:00AM  NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference Business Wire
May-31-19 08:00AM  NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting Business Wire
May-23-19 10:13AM  What Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)? Simply Wall St. -7.27%
May-01-19 08:00AM  Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwests NK-92® Cells Business Wire
Apr-01-19 08:00AM  NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate Business Wire
05:42AM  Will NantKwest Continue to Surge Higher? Zacks
Mar-25-19 08:00AM  NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NKs Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy Business Wire +32.54%
Mar-18-19 05:00AM  NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit Business Wire
Mar-04-19 08:00AM  NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics Business Wire -9.85%
Feb-25-19 02:13PM  Our Take On NantKwest, Inc.s (NASDAQ:NK) CEO Salary Simply Wall St.
Jan-10-19 08:50AM  Is the Options Market Predicting a Spike in NantKwest (NK) Stock? Zacks
Jan-09-19 08:00AM  NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNK Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy Business Wire
Jan-07-19 03:36PM  Soon-Shiongs NantCell gets $30 million from Celgene American City Business Journals
Jan-05-19 08:00AM  NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs Business Wire
Dec-25-18 10:03AM  Have Insiders Been Selling NantKwest, Inc. (NASDAQ:NK) Shares? Simply Wall St.
Dec-18-18 10:30AM  Is Nantkwest Inc (NK) Going to Burn These Hedge Funds? Insider Monkey
Dec-03-18 11:00AM  NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology Business Wire
Nov-08-18 12:56PM  Here's Why NantKwest Skyrocketed 26.4% Today Motley Fool +37.27%
10:20AM  Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc. ACCESSWIRE
Nov-07-18 05:28PM  NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy Business Wire
Nov-05-18 11:23PM  NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference Business Wire
Oct-23-18 08:00AM  Investor Expectations to Drive Momentum within Navios Maritime Partners LP, Alliance Data, Eli Lilly, CONVERGEONE HLD, Atkore International Group, and NantKwest Discovering Underlying Factors of Influence GlobeNewswire
06:05AM  NantKwest Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-02-18 12:02PM  NantKwest to Present at 2018 Cantor Global Healthcare Conference Business Wire +10.11%
Sep-18-18 01:52PM  Who Are The Top Investors In NantKwest Inc (NASDAQ:NK)? Simply Wall St.
Aug-29-18 08:30AM  Report: Exploring Fundamental Drivers Behind Navios Maritime Partners LP, CONVERGEONE HLD, Greenbrier Companies, NantKwest, Genpact, and Textainer Group New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-10-18 03:08PM  Citigroup Upgrades NantKwest, But Finds Six Reasons To Stay On Sidelines Benzinga
Jul-02-18 08:10AM  Report: Exploring Fundamental Drivers Behind Telecom Argentina, GasLog, National Retail Properties, Appian, Zscaler, and NantKwest New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -6.21%
Jun-19-18 05:00AM  NantKwest Names Sonja Nelson Chief Financial Officer Business Wire -8.20%
Jun-11-18 07:08AM  Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO Reuters
07:00AM  Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO Reuters
Jun-05-18 01:29PM  NantKwest to Present at Jefferies 2018 Global Healthcare Conference Business Wire
Apr-23-18 03:18PM  NantKwest to Present at Upcoming Science & Medicine Conferences Business Wire
Mar-13-18 07:29PM  NantKwest to Present at Upcoming Investment and Healthcare Conferences Business Wire -6.72%
02:49PM  Rockville biotech founded by L.A. billionaire to lay off 52 American City Business Journals
Feb-13-18 08:00AM  Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Carnatural Killer) Cell Therapy in Glioblastoma Business Wire
Feb-06-18 08:25AM  New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-30-18 09:06AM  Putin says U.S. is taking 'hostile step' Yahoo Finance
07:20AM  Yahoo Finance Live: Market Movers - Jan 30th, 2018 Yahoo Finance Video
Jan-24-18 02:05PM  3 Stocks Under $10 That Surged Yesterday InvestorPlace
Jan-23-18 06:44PM  3 Stocks Under $10 That Surged Today Zacks
Jan-05-18 06:03PM  NantWorks to Present Healthcare and Biotechnology Platforms at 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018 in San Francisco, CA Business Wire
03:44AM  NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine Business Wire
Dec-28-17 12:30PM  ETFs with exposure to NantKwest, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:35AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-12-17 09:45AM  Update in Lawsuit for Investors in Nantkwest Inc. (NASDAQ: NK) Shares Announced by Shareholders Foundation ACCESSWIRE
Dec-04-17 08:00AM  NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology Business Wire
Nov-21-17 07:59AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : November 21, 2017 Capital Cube
Oct-24-17 04:51PM  Lifshitz & Miller LLP Announces Investigation of AmTrust Financial Services Inc., Axon Enterprise, Inc., Diana Containerships Inc., Kobe Steel, Ltd., NantKwest, Inc., Skechers U.S.A., Inc. and Tesla, Inc. PR Newswire
Oct-11-17 11:52AM  ETFs with exposure to NantKwest, Inc. : October 11, 2017 Capital Cube
Oct-04-17 09:30AM  Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact Firm PR Newswire
Sep-26-17 10:59AM  ETFs with exposure to NantKwest, Inc. : September 26, 2017 Capital Cube
Sep-22-17 04:39PM  NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors Business Wire
Sep-21-17 08:01AM  NANTKWEST (NK) SHAREHOLDER ALERT Andrews & Springer LLC is Investigating NantKwest, Inc. for Potential Breaches of Fiduciary Duty Business Wire
Aug-31-17 07:38PM  ETFs with exposure to NantKwest, Inc. : August 31, 2017 Capital Cube
Aug-24-17 10:11AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-15-17 06:18PM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : August 15, 2017 Capital Cube
Aug-09-17 11:50AM  Here's Why NantKwest Inc. Tumbled 21.1% in July Motley Fool
Aug-07-17 12:59PM  NantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference Business Wire
Aug-02-17 09:12AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : August 2, 2017 Capital Cube
Jul-31-17 11:00AM  NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies Business Wire
Jul-27-17 09:00AM  Haeggquist & Eck Investigates NantKwest for Misrepresenting Compensation to CEO by $49 Million and Breach of Fiduciary Duty Business Wire
Jul-25-17 08:00AM  NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials Business Wire
Jul-18-17 08:10AM  5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote Zacks
Jul-14-17 09:00AM  Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors Business Wire
Jun-21-17 09:30AM featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago Zacks
Jun-20-17 05:37PM  How to Uncover Institutional Buying Zacks
Jun-19-17 03:48PM  ETFs with exposure to NantKwest, Inc. : June 19, 2017 Capital Cube
Jun-16-17 08:15AM  NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session Zacks
Jun-14-17 02:09PM  2 Longs And 2 Shorts To Watch Benzinga
Jun-06-17 08:00AM  NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease Business Wire
Jun-02-17 06:55AM  NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017 Business Wire
May-23-17 09:29AM  Biotech Movers: Cerus, Alexion, NantKwest
May-18-17 08:00AM  NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs Business Wire
May-16-17 05:02PM  Why Rite Aid, H&R Block, and NantKwest Slumped Today Motley Fool
08:00AM  NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology Business Wire
May-15-17 06:24PM  NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference Business Wire
04:15PM  ETFs with exposure to NantKwest, Inc. : May 15, 2017 Capital Cube
02:34PM  Why NantKwest Stock Is Spiking Today Motley Fool
08:17AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : May 15, 2017 Capital Cube
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomas John CDirectorDec 16Sale3.1410,00031,400330,069Dec 16 07:40 PM
Thomas John CDirectorDec 13Sale2.7320,00054,600340,069Dec 16 07:40 PM
Thomas John CDirectorDec 12Sale1.9910,00019,918360,069Dec 12 06:29 PM
Thomas John CDirectorSep 09Sale1.2413,95617,305370,069Sep 09 04:42 PM
Thomas John CDirectorSep 06Sale1.247,0808,779384,025Sep 09 04:42 PM
Thomas John CDirectorSep 05Sale1.252,9643,705391,105Sep 09 04:42 PM
Nelson SonjaChief Financial OfficerAug 02Option Exercise0.0010,000025,000Aug 05 05:46 PM
SOON-SHIONG PATRICKChairman and CEOMar 21Option Exercise2.201,851,5004,070,15220,040,750Mar 21 09:06 PM